Prevalence of seroprotection against the pandemic (H1N1) virus after the 2009 pandemic
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Before pandemic (H1N1) 2009, less than 10% of serum samples collected from all age groups in the Lower Mainland of British Columbia, Canada, showed seroprotection against the pandemic (H1N1) 2009 virus, except those from very elderly people. We reassessed this profile of seroprotection by age in the same region six months after the fall 2009 pandemic and vaccination campaign. METHODS: We evaluated 100 anonymized serum samples per 10-year age group based on convenience sampling. We measured levels of antibody against the pandemic virus by hemagglutination inhibition and microneutralization assays. We assessed geometric mean titres and the proportion of people with seroprotective antibody levels (hemagglutination inhibition titre ≥ 40). We performed sensitivity analyses to evaluate titre thresholds of 80, 20 and 10. RESULTS: Serum samples from 1127 people aged 9 months to 101 years were obtained. The overall age-standardized proportion of people with seroprotective antibody levels was 46%. A U-shaped age distribution was identified regardless of assay or titre threshold applied. Among those less than 20 years old and those 80 years and older, the prevalence of seroprotection was comparably high at about 70%. Seroprotection was 44% among those aged 20-49 and 30% among those 50-79 years. It was lowest among people aged 70-79 years (21%) and highest among those 90 years and older (88%). INTERPRETATION: We measured much higher levels of seroprotection after the 2009 pandemic compared than before the pandemic, with a U-shaped age distribution now evident. These findings, particularly the low levels of seroprotection among people aged 50-79 years, should be confirmed in other settings and closer to the influenza season.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epidemiology of fatal cases associated with pandemic H1N1 influenza 2009.
Vaillant, L., La Ruche, G., Tarantola, A., Barboza, P., & for the epidemic intelligence team at InVS (2009) · Eurosurveillance · doi:10.2807/ese.14.33.19309-en · Cited by 348
Collins, S. D. (1931) · Public Health Reports (1896-1970) · doi:10.2307/4580139 · Cited by 81
Cited by
Kelly, H., Peck, H. A., Laurie, K. L., Wu, P., Nishiura, H., & Cowling, B. J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021828 · Cited by 295
Zhou, X., & McElhaney, J. E. (2011) · Vaccine · doi:10.1016/j.vaccine.2010.12.029 · Cited by 106
“Protective antibody titers against pH1N1 were mainly observed in those adults over age 80 years old [38] and this was consistent with very low attack rates in this subset of older adults.”
ResultSelf-citationKhurana, S., Frasca, D., Blomberg, B., & Golding, H. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1002920 · Cited by 85
“Although it has been reported that archived plasma samples from elderly $80 years of age have increased neutralization titers to the H1N1pdm09 [13], the initial titers in young and elderly individuals in our cohorts were not significantly different (reciprocal titers at t0: 74612 and 108639 in young versus elderly, re…”
BackgroundUnique biomarkers for B-cell function predict the serum response to pandemic H1N1 influenza vaccine
Frasca, D., Diaz, A., Romero, M., Phillips, M., Mendez, N. V., Landin, A. M., & Blomberg, B. B. (2012) · International Immunology · doi:10.1093/intimm/dxr123 · Cited by 86
(2022) · doi:10.1503/cmaj.221335 · Cited by 69
Metadata
- Authors
- Skowronski, D. M., Hottes, T. S., Janjua, N. Z., Purych, D., Sabaiduc, S., Chan, T., De Serres, G., Gardy, J., McElhaney, J. E., Patrick, D. M., & Petric, M.
- Venue
- Canadian Medical Association Journal
- Publisher
- CMA Joule Inc.
- Published
- 2010-10-18
- Volume
- 182
- Issue
- 17
- Pages
- 1851-1856
- ISSN
- 0820-3946 (ISSN-L)
- 1488-2329
- OpenAlex
- W2097399384
- Cited by
- 48
- References
- 2
- FWCI
- 6.71
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.